CD274 and renal cell carcinoma: The combination of PD-L1 inhibitor atezolizumab and bevacizumab also showed safety and observed longer PFS in PD-L1 positive subgroup of patients with advanced renal cell carcinoma (RCC) [51]; the mPFS was 11.2 months for atezolizumab plus bevacizumab versus 7.7 months for sunitinib in PD-L1-positive patients [52].